Your email has been successfully added to our mailing list.

×
0 0 0 0.0735947214820454 0.0808273061794189 0.0253774901662226 0.0367339170156071 0.0399061032863849
Stock impact report

Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters]

Gilead Sciences, Inc. (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Company Research Source: Reuters
Gilead's remdesivir meets main goal of trial in COVID-19 patients (Reuters) - Gilead Sciences Inc said on Wednesday its experimental antiviral drug, remdesivir, had met the main goal of a trial testing it in COVID-19 patients. The trial was being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), and more details on the data would be provided at an upcoming briefing by the NIAID, Gilead said. Show less Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for GILD alerts
Opt-in for
GILD alerts

from News Quantified
Opt-in for
GILD alerts

from News Quantified